N
CTMX icon

Nuveen’s CytomX Therapeutics CTMX Stock Holding History

Nuveen’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-200,943
Closed -$621K – 3295
2022
Q1 		$621K Buy
200,943
+1,413
+0.7% +$5.43K ﹤0.01% 2950
2021
Q4 		$1.23M Sell
199,530
-23,936
-11% -$140K ﹤0.01% 2782
2021
Q3 		$1.17M Buy
223,466
+32,365
+17% +$173K ﹤0.01% 2933
2021
Q2 		$1.21M Sell
191,101
-373,466
-66% -$2.91M ﹤0.01% 2941
2021
Q1 		$4.37M Sell
564,567
-45,829
-8% -$363K ﹤0.01% 2227
2020
Q4 		$4M Sell
610,396
-20,523
-3% -$147K ﹤0.01% 2184
2020
Q3 		$4.2M Sell
630,919
-92,882
-13% -$689K ﹤0.01% 2014
2020
Q2 		$6.03M Buy
723,801
+2,833
+0.4% +$26.3K ﹤0.01% 1797
2020
Q1 		$5.53M Buy
720,968
+18,660
+3% +$130K ﹤0.01% 1652
2019
Q4 		$5.84M Sell
702,308
-41,278
-6% -$279K ﹤0.01% 1903
2019
Q3 		$5.49M Sell
743,586
-814
-0.1% -$8.03K ﹤0.01% 1902
2019
Q2 		$8.35M Buy
+744,400
New +$7.8M ﹤0.01% 1717

Other funds holding CTMX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Nuveen's CTMX Position: Q2 2022 in Review

Nuveen sold out of CytomX Therapeutics (CTMX) in Q2 2022, closing a stake of 200,943 shares — an estimated $621K sold.

Nuveen first reported a position in CTMX in Q2 2019 and held it in 12 quarters. The position peaked at $8.35M in Q2 2019. 98 funds tracked by Wall St. Rank hold CTMX as of Q2 2022.

  • Nuveen reported no remaining CytomX Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Nuveen sold 200,943 CytomX Therapeutics shares in Q2 2022, an estimated $621K.
  • Nuveen first reported a position in CytomX Therapeutics in Q2 2019 and held it in 12 quarters.
  • Nuveen's CytomX Therapeutics position peaked at $8.35M in Q2 2019.
  • 98 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2022.

Based on Nuveen's 13F filing for Q2 2022, filed 15 Aug 2022.